Raymond James Reinstates Market Perform on Qualcomm
Raymond James analyst Srini Pajjuri reinstates Qualcomm (NASDAQ:QCOM) with a Market Perform.
Raymond James Reinstates Outperform on Qorvo, Announces $120 Price Target
Raymond James analyst Srini Pajjuri reinstates Qorvo (NASDAQ:QRVO) with a Outperform and announces $120 price target.
Needham Reinstates Hold on Tesla
Needham analyst Chris Pierce reinstates Tesla (NASDAQ:TSLA) with a Hold.
Barclays Initiates Coverage On KKR & Co with Overweight Rating, Announces Price Target of $69
Barclays analyst Benjamin Budish initiates coverage on KKR & Co (NYSE:KKR) with a Overweight rating and announces Price Target of $69.
Barclays Initiates Coverage On Carlyle Group with Overweight Rating, Announces Price Target of $41
Barclays analyst Benjamin Budish initiates coverage on Carlyle Group (NASDAQ:CG) with a Overweight rating and announces Price Target of $41.
Raymond James Assumes Broadcom at Market Perform
Raymond James analyst Srini Pajjuri assumes Broadcom (NASDAQ:AVGO) with a Market Perform rating.
Rosenblatt Initiates Coverage On Stagwell with Buy Rating, Announces Price Target of $10
Rosenblatt analyst Barton Crockett initiates coverage on Stagwell (NASDAQ:STGW) with a Buy rating and announces Price Target of $10.
Raymond James Assumes NVIDIA at Strong Buy, Announces Price Target of $290
Raymond James analyst Chris Caso assumes NVIDIA (NASDAQ:NVDA) with a Strong Buy rating and announces Price Target of $290.
RBC Capital Initiates Coverage On Moderna with Outperform Rating, Announces Price Target of $200
RBC Capital analyst Luca Issi initiates coverage on Moderna (NASDAQ:MRNA) with a Outperform rating and announces Price Target of $200.
AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says
Guggenheim initiated coverage on AbbVie Inc (NYSE:ABBV) with a Buy and a price target of $172 on diversified growth. Investors have “naturally” been…